Research Gives Green Light for Migraine Relief
A pilot study suggests that exposure to green light of a particular wavelength and brightness may be as effective as drugs in reducing the frequency and severity of migraine. Read more.
Largescale Real-World Migraine Study Solidifies Efficacy and Safety of Theranica’s Nerivio® Device
Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced the publication of a new real-world post-marketing surveillance study in Pain Medicine that demonstrates the safety, efficacy and [...]
The Prevalence of Restless Legs Syndrome in Patients with Migraine: A Systematic Review and Meta-Analysis
Migraine is a severe and debilitating neurologic disorder and is claimed to be the sixth disabling illness in the world. This study aimed to determine the overall prevalence of restless legs syndrome (RLS) in patients [...]
Microstructural Changes in the Trigeminal Nerve of Patients With Episodic Migraine Assessed Using Magnetic Resonance Imaging
There is histological evidence of microstructural changes in the zygomaticotemporal branch of the trigeminal nerve in migraineurs. This raises the possibility that altered trigeminal nerve properties contribute to migraine pathophysiology. Whilst it is not possible [...]
Nightly Sleep Duration, Fragmentation, and Quality and Daily Risk of Migraine.
Abstract: Objective: To test the hypotheses that insufficient duration, high fragmentation, and poor sleep quality are temporally associated with migraine onset on the day immediately following the sleep period (day 0) and the following day (day [...]
Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with a History of Inadequate Response
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that AXS-07, Axsome's novel, oral, multi-mechanistic investigational medicine for the acute treatment of migraine, [...]
FDA Approves New Treatment for Patients with Migraine
The U.S. Food and Drug Administration approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. Reyvow is not indicated [...]
New Data for Migraine Treatment
New research showed that, overall, opioids are being used in place of medicines that are approved and indicated to treat migraine – particularly among those who experience migraine headaches more frequently. Full story.
June is National Migraine & Headache Awareness Month
Bring awareness and recognition of headache disorder as a legitimate neurobiological disease and help make individuals with headache disorder know that there are new treatments available. Read about the AAPM Foundation's Migraine Consensus Guideline project [...]
FDA Grants Theranica De Novo to Market First Smartphone-controlled Acute Migraine-relief Wearable Device
Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other pain disorders, announced today that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra®, [...]